Drugs / HCC antigens-specific CD8+ T lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03175705 | May 2017 → Dec 2018 | hepatocellular carcinoma | Beijing YouAn Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCC antigens-specific CD8+ T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03175705 ↗ |
| Known as | specific HCC antigens CD8+ T cells | “This research study uses specific HCC antigens CD8+ T cells, a new experimental treatment.” NCT03175705 ↗ |
| Modality | Cell therapy | “The purpose of this study is to evaluate the safety and tolerance as well as the potential clinical efficacy of an adoptive transfer of CD8+ T cells” NCT03175705 ↗ |